XOMA (XOMA) Cut to Sell at ValuEngine

ValuEngine cut shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report published on Wednesday, May 1st, ValuEngine reports.

Other equities research analysts also recently issued research reports about the company. HC Wainwright set a $30.00 target price on XOMA and gave the company a buy rating in a report on Friday, April 12th. Zacks Investment Research raised XOMA from a sell rating to a hold rating in a research report on Saturday, March 9th. Finally, Wedbush reaffirmed a buy rating and set a $26.00 target price on shares of XOMA in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. XOMA has an average rating of Hold and an average price target of $23.75.

NASDAQ:XOMA traded up $0.59 during trading hours on Wednesday, reaching $16.18. 87,265 shares of the company were exchanged, compared to its average volume of 53,401. The company has a market capitalization of $136.97 million, a P/E ratio of -10.18 and a beta of 2.38. XOMA has a 1-year low of $11.02 and a 1-year high of $25.99. The company has a debt-to-equity ratio of 1.13, a current ratio of 7.20 and a quick ratio of 7.20.

XOMA (NASDAQ:XOMA) last issued its earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.33. The firm had revenue of $8.13 million for the quarter, compared to the consensus estimate of $3.23 million. XOMA had a negative return on equity of 51.66% and a negative net margin of 48.62%. On average, sell-side analysts anticipate that XOMA will post -1.18 EPS for the current fiscal year.

In other news, major shareholder Bvf Partners L. P/Il bought 3,797 shares of XOMA stock in a transaction dated Monday, May 13th. The stock was bought at an average cost of $14.36 per share, for a total transaction of $54,524.92. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Bvf Partners L. P/Il bought 10,300 shares of XOMA stock in a transaction dated Friday, May 10th. The stock was purchased at an average price of $14.57 per share, with a total value of $150,071.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 42,010 shares of company stock valued at $612,963. Company insiders own 9.89% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. California Public Employees Retirement System grew its stake in shares of XOMA by 11.5% in the 4th quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,220 shares during the period. BlackRock Inc. grew its stake in shares of XOMA by 0.8% in the 3rd quarter. BlackRock Inc. now owns 452,542 shares of the biotechnology company’s stock valued at $7,951,000 after buying an additional 3,686 shares during the period. Fosun International Ltd acquired a new stake in shares of XOMA in the 4th quarter valued at about $3,842,000. Pennsylvania Trust Co acquired a new stake in shares of XOMA in the 1st quarter valued at about $3,531,000. Finally, Chicago Equity Partners LLC acquired a new position in XOMA during the 4th quarter valued at about $501,000. Institutional investors own 48.71% of the company’s stock.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Read More: What is a trade deficit?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.